KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 9,550 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 9,550 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $193,101.00. Following the transaction, the chief executive officer owned 462,577 shares in the company, valued at approximately $9,353,306.94. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $20.87 on Tuesday. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -5.28 and a beta of -0.40. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.83 and a 1-year high of $21.31. The company’s fifty day simple moving average is $17.50 and its 200 day simple moving average is $15.23. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Seven Fleet Capital Management LP acquired a new position in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $782,000. Invesco Ltd. grew its stake in shares of KalVista Pharmaceuticals by 23.1% in the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 14,621 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $428,000. Vestal Point Capital LP grew its stake in shares of KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares in the last quarter. Finally, Virtus Investment Advisers LLC grew its stake in shares of KalVista Pharmaceuticals by 364.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock valued at $653,000 after acquiring an additional 31,721 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on KALV shares. Stifel Nicolaus boosted their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Citizens Jmp decreased their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 26th. Needham & Company LLC upped their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Finally, Wall Street Zen downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.